Free Access
Med Sci (Paris)
Volume 36, Number 2, Février 2020
Page(s) 141 - 146
Section M/S Revues
Published online 04 March 2020
  1. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Genet 2019; Sep 16. doi: 10.1038/s41431-019-0508-0. [Google Scholar]
  2. Weissenbach J, Gyapay G, Dib C, et al. A second-generation linkage map of the human genome. Nature 1992 ; 359 : 794–801. [Google Scholar]
  3. Cohen D, Chumakov I, Weissenbach J. A first-generation physical map of the human genome. Nature 1993 ; 366 : 698–701. [Google Scholar]
  4. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995 ; 80 : 155–165. [CrossRef] [PubMed] [Google Scholar]
  5. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996 ; 15 : 3555–3565. [PubMed] [Google Scholar]
  6. Zhang Z, Pinto AM, Wan L, et al. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc Natl Acad Sci USA 2013 ; 110 : 19348–19353. [CrossRef] [Google Scholar]
  7. Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci 2017 ; 8 : 1–6. [PubMed] [Google Scholar]
  8. Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies. Neurology 2019 ; 92 : e2492–e2506. [Google Scholar]
  9. Finkel R, Chiriboga C, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016 ; 388 : 3017–3026. [CrossRef] [PubMed] [Google Scholar]
  10. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019 ; S0960–8966 : 31127–31127. [Google Scholar]
  11. Guettier-Sigrist S, Coupin G, Braun S, et al. On the possible role of muscle in the pathogenesis of spinal muscular atrophy. Fundam Clin Pharmacol 2001 ; 15 : 31–40. [CrossRef] [PubMed] [Google Scholar]
  12. Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011 ; 20 : 681–693. [CrossRef] [PubMed] [Google Scholar]
  13. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009 ; 27 : 59–65. [CrossRef] [PubMed] [Google Scholar]
  14. ICER - Institute for Clinical and Economical Review - A look at Spinraza and ZolgenSMA, April 2019, pp. 1–8. [Google Scholar]
  15. Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag 2019 ; 15 : 1153–1161. [PubMed] [Google Scholar]
  16. Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 2018 ; 6 : e00447. [CrossRef] [PubMed] [Google Scholar]
  17. Bowerman M, Becker CG, Yáñez-Muñoz RJ, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech 2017 ; 10 : 943–954. [Google Scholar]
  18. Barkats M. SMA : de la découverte du gène à la thérapie génique. Med Sci (Paris) 2020; 36 : 137–40. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.